Patents Examined by Jeffrey S. Parkin
  • Peptides derived from viral proteins for use as immunogens and dosage reactants
    Patent number: 10501499
    Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 10, 2019
    Assignee: BIONOR IMMUNO AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold
  • Methods for reducing viral load in HIV-1 infected patients
    Patent number: 10500274
    Abstract: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 10, 2019
    Assignee: CytoDyn Inc.
    Inventors: William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
  • Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
    Patent number: 10500264
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 10, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Variant angola marburg virus
    Patent number: 10466231
    Abstract: The present invention includes methods of making, and compositions comprising, a uniformly lethal filovirus for outbred small mammals by mutation of the viral genome through serial passages in a small mammal, the method comprising the steps of: obtaining a filovirus strain from a human subject; passing the filovirus strain one or more times by intramuscular injection of one or more filovirus infected tissues into an inbred small mammal until uniform lethality is obtained; passing the filovirus strain in one or more human cell lines; passing the filovirus strain one or more times by intraperitoneal injection of one or more filovirus infected tissues into an outbred small mammal until uniform lethality is obtained; and isolating the uniformly lethal filovirus obtained thereby.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 5, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joan B. Geisbert, Chad E. Mire, Thomas W. Geisbert, Robert W. Cross
  • Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
    Patent number: 10449245
    Abstract: The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel methods for treatment of HIV infection and prevention of AIDS.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: October 22, 2019
    Assignee: Bionor Immuno AS
    Inventors: Anker Lundemose, Mats Ökvist, Arnt Ove Hovden, Maja Sommerfelt Grønvold
  • Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins
    Patent number: 10444245
    Abstract: The disclosure relates to a virus-like particle in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting the protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of protein complexes.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: October 15, 2019
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Sven Eyckerman
  • Sin Nombre virus full-length M segment-based DNA vaccines
    Patent number: 10443073
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 15, 2019
    Assignee: The Government of the United States, as represented by the Secretary of the Army
    Inventor: Jay Hooper
  • Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus
    Patent number: 10421978
    Abstract: The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 24, 2019
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bernard Moss, Linda S. Wyatt, Patricia L. Earl
  • Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
    Patent number: 10421803
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 24, 2019
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Method of inducing an immune response by administering exosomes comprising Nef-fusion proteins
    Patent number: 10414804
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: September 17, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali
  • Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag
    Patent number: 10407470
    Abstract: Provided herein are HIV vaccines that encompasses recombinant trimers that mimic native HIV-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an HIV vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. A recombinant trimer is formed by a recombinant protein comprising a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140, wherein the linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix during purification of the recombinant trimer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 10, 2019
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Wadad Alsalmi
  • Broadly neutralizing antibody directed against HIV-1 GP140
    Patent number: 10392433
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 27, 2019
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
    Patent number: 10376583
    Abstract: This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: August 13, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Dan H. Barouch
  • Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
    Patent number: 10377815
    Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 13, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
  • Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
    Patent number: 10370417
    Abstract: The present invention relates to methods and kits for diagnosis of cancer in a subject by detecting human endogenous retrovirus env (HERV-WL) polypeptides.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: August 6, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Vincent K. Tsiagbe, Yu Li
  • Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
    Patent number: 10369214
    Abstract: Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins
    Patent number: 10369208
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: August 6, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • Single domain antibodies directed against ebola virus VP24
    Patent number: 10369223
    Abstract: This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: August 6, 2019
    Assignee: Singh Biotechnology, LLC
    Inventor: Sunanda Singh
  • Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
    Patent number: 10335482
    Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilization of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 2, 2019
    Assignee: BIONOR IMMUNO AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
  • Methods for evaluating viral clearance from a process solution employing mock viral particles
    Patent number: 10309963
    Abstract: The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
    Type: Grant
    Filed: March 11, 2017
    Date of Patent: June 4, 2019
    Assignee: MockV Solutions, Inc.
    Inventors: David Cetlin, Arun Dhar